CANF - Can-Fite BioPharma Ltd.

NYSE American - Nasdaq Real Time Price. Currency in USD
1.3500
0.0000 (0.00%)
At close: 3:58PM EDT

1.3500 0.00 (0.00%)
After hours: 4:57PM EDT

Stock chart is not supported by your current browser
Previous Close1.3500
Open1.4100
Bid1.2600 x 800
Ask1.4200 x 4000
Day's Range1.2230 - 1.4900
52 Week Range1.0000 - 1.7300
Volume429,370
Avg. Volume232,835
Market Cap30.242M
Beta (3Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-0.2600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • ACCESSWIREyesterday

    Four Marijuana Stocks on the Rise on Wednesday

    Whereas in the past, society largely condemned cannabis and refused to consider the potential benefits of investing in cannabis and/or utilizing cannabis products, those feelings are slowly dissipating. The positive shift in public opinion can be attributed to the fact that the medical community has released data supporting the use of cannabidiol as a form of alternative treatment, given its effectiveness as an anti-inflammatory. Like other sectors whirring with innovation, the cannabis industry is rapidly progressing into the future and, rather than be left behind, investors looking for potential opportunities may want to keep cannabis companies on their radars.

  • Business Wire22 days ago

    Can-Fite to Participate in Bio Asia International Conference on March 5-6, 2019 in Tokyo

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the Company’s VP of Business Development, Sari Fishman will participate in the Bio Asia International Conference in Tokyo, Japan on March 5th and 6th, 2019. The BIO Asia International Conference brings together the global biotechnology and pharmaceutical industry to explore licensing collaborations and investor engagement in the current Asia-Pacific business and policy environments.

  • Business Wire24 days ago

    Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the expansion of its distribution agreement with Chong Kun Dang Pharmaceuticals (CKD) (Korean Stock Exchange: 185750.KS) in South Korea, for the indication of non-alcoholic steatohepatitis (NASH).

  • ACCESSWIRElast month

    Watch These 4 Healthcare Stocks Set The Pace On Monday (2/4/19)

    Over time, in an effort to further these advancements in the healthcare industry, legislators have sought to pass positive legislation in favor of legalizing marijuana, resulting in the passing of the US Farm Bill as well as other laws around the world. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Can-Fite BioPharma Ltd (CANF), BioLineRx Ltd (BLRX), and Aurora Cannabis Inc., (ACB) represent four cannabis companies determined to develop nuanced approaches for integrating cannabis as a means for improving the quality of life for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • Business Wirelast month

    Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug

    Osteoarthritis is a common joint disease impacting ageing populations and represents an $8 billion global treatment market in 2017 and is expected to rise to $11.6 billion by the end of 2025 according to Persistence Market Research.

  • ACCESSWIRE2 months ago

    4 Healthcare Stocks Raising The Bar On Wednesday (1/30/19)

    With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Co-Diagnostics Inc (CODX), Can-Fite BioPharma Ltd (CANF), and Eyenovia Inc (EYEN) represent four healthcare companies determined to develop and distribute the best quality healthcare options for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • Business Wire2 months ago

    Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

    Can-Fite’s Piclidenoson, a Phase III drug candidate, and Namodenson, a Phase II drug candidate, both target the A3 adenosine receptor (A3AR), which the Company believes may treat cytokine release syndrome (CRS) while also promoting an anti-cancer effect.

  • Business Wire2 months ago

    Can-Fite BioPharma CEO Letter to Shareholders

    It has been a very busy and productive year at Can Fite BioPharma, filled with clinical and business development activities. During 2018, we continued to enroll patients for the ACRobat™ Phase III trial of our lead drug candidate, Piclidenoson, in the treatment of rheumatoid arthritis and in August 2018, we initiated patient enrolment for a the Comfort™ Phase III psoriasis trial.

  • Business Wire2 months ago

    Can-Fite BioPharma Announces Registered Direct Offering

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive agreement with a single institutional investor to receive gross proceeds of approximately $2.35 million. In connection with the offering, the Company will issue 2,238,096 registered American Depository Shares (ADSs) of Can-Fite at a purchase price of $1.05 per ADS in a registered direct offering.

  • Business Wire2 months ago

    Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced new pre-clinical findings demonstrating that Namodenoson, inhibits lipid production and fat accumulation in adipocytes (lipid producing cells). These findings together with the excellent safety profile of Namodenoson support its potential utilization as an anti-obesity drug. New pre-clinical studies of Namodenoson showed a significant decrease in lipid production and fat accumulation utilizing 3T3-L1 adipocytes, functioning as lipid producing cells and are also responsible for fat storage.

  • Business Wire3 months ago

    Can-Fite to Participate in the Biotech Showcase™ 2019 and BIO One-on-One Partnering™@ JPM 2019 During the JP Morgan Healthcare Conference

    Can-Fite’s near term milestones include data release from a Phase II study with its Namodenoson drug in patients with advanced liver cancer which is expected in Q1/19. In addition, the Company is actively enrolling NAFLD/NASH patients for a Phase II study of Namodenoson.

  • Business Wire3 months ago

    Can-Fite Enters Into Collaboration Agreement to Explore Namodenoson’s Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC

    The agreement will support research directed by Scott Friedman, M.D., Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine. The research is aimed at transcriptomic and molecular analyses to further explore the mechanisms of action of Namodenoson (CF102) in human hepatic stellate cells in order to clarify its effect on fibrogenesis that occurs in non-alcoholic steatohepatitis (NASH).

  • Business Wire4 months ago

    Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update

    Revenues for the Nine Months Ended September 30, 2018 Were $3.5 Million Compared to $0.7 Million for the Same Period in 2017

  • Business Wire4 months ago

    Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert

    PETACH TIKVA, Israel-- -- Dr. Josep Llovet is a Key Opinion Leader in the field of liver diseases Data from Phase II study in advanced liver cancer are expected during Q1 2019 Can-Fite BioPharma Ltd . , a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced that Professor Josep Llovet, an experienced leader with deep ...

  • Business Wire5 months ago

    Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19

    Namodenoson has received Fast Track Status in the U.S. and Orphan Drug Designation in Europe and the U.S. In order to maintain the statistical integrity of the trial as well as adhere to the principles of Good Clinical Practice, the Company estimates that it will un-blind the data during Q1/19.

  • Business Wire5 months ago

    Can-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference

    Dr. Fishman will present the molecular mechanism mediating the anti-cancer effects of Namodenoson and will describe clinical data from the Company’s earlier Phase I/II liver cancer study. In addition, she will present the status of the current Phase II study in patients with advanced hepatocellular carcinoma, Child Pugh B. Patients with advanced HCC, Child Pugh B, who failed Nexavar (sorafenib) as a first line treatment are treated twice daily with 25 mg of oral Namodenoson or placebo using a 2:1 randomization.

  • Business Wire5 months ago

    Can-Fite CEO to present as Expert Speaker on Namodenoson at NASH Summit Europe 2018

    “I am pleased to be invited to speak at NASH Summit Europe and to share Can-Fite’s Namodenoson molecular mechanism of action in inhibiting the manifestations of NAFLD/NASH. Namodenoson represents a novel therapy approach for the treatment of NASH and its precursor, non-alcoholic fatty liver disease (NAFLD).

  • Business Wire6 months ago

    Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD)

    Can Fite will present data generated recently in histological studies utilizing the CCL4 NAFLD/NASH model, demonstrating a significant decrease in liver fibrosis upon chronic treatment with Namodenoson, as measured by Sirius Red staining followed by morphometric digital analysis. Similar data were also reproduced in a human hepato-stelatte cell line demonstrating significant decrease in α-SMA expression level, a specific fibrosis bio-marker.

  • Business Wire7 months ago

    Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year

    Namodenoson has received Fast Track Status in the U.S. and Orphan Drug Designation in Europe and the U.S. Top line efficacy results are expected by end of year. The global Phase II study is being conducted in the U.S., Europe and Israel.

  • Business Wire7 months ago

    Can-Fite Reports Second Quarter 2018 Financial Results and Provides Clinical Update

    - Company signed a multi-million dollar development and distribution agreement for Piclidenoson and Namodenoson in China with CMS Medical and received an upfront payment of $2M

  • Business Wire7 months ago

    Can-Fite BioPharma Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018

    Can-Fite BioPharma (CANF), today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. Motti Farbstein, CFO of Can-Fite, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com ) to register for the conference.

  • Business Wire7 months ago

    Can-Fite Announces Enrollment of First Patient in its Comfort™ Phase III Trial of Piclidenoson in Psoriasis

    The Comfort™ Phase III Psoriasis study, is designed to evaluate the efficacy and safety of daily Piclidenoson, administered orally compared to Apremilast (Otezla®) and placebo, in 407 patients with moderate-to-severe plaque psoriasis. The study will be conducted in 5 countries in Europe, Israel and Canada.

  • Business Wire7 months ago

    Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China

    Can-Fite recently announced entering into a development, registration and marketing agreement with CMS for the exclusive right of Can-Fite’s lead drug candidates, Piclidenoson (CF101), for the treatment of rheumatoid arthritis and psoriasis & Namodenoson (CF102) for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). The recently signed CMS agreement adds to the agreements that the Company already has in place with Cipher Pharmaceuticals (for the distribution of Piclidenoson in Canada for rheumatoid arthritis and psoriasis), Kwang Dong Pharmaceutical (for the distribution of Piclidenoson in South Korea for rheumatoid arthritis), Chong Kun Dang (for distribution of Namodenoson in South Korea for treatment of liver cancer) and Gebro Pharma (for the distribution of Piclidenoson in Spain, Switzerland and Austria).

  • Business Wire7 months ago

    Can-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical

    Upfront and milestone payments total up to $74.5M plus double-digit royalties

  • Reuters7 months ago

    BRIEF-China Medical System Holdings Says It Signed License, Collaboration & Distribution Agreement

    Aug 6 (Reuters) - China Medical System Holdings Ltd : * THROUGH UNIT SIGNED A LICENSE, COLLABORATION AND DISTRIBUTION AGREEMENT WITH CAN-FITE BIOPHARMA LTD Source text for Eikon: Further company coverage:...